Astonea Labs Ltd. Secures Shareholder Approval for IPO Object Variation
Astonea Labs Limited announced on March 27, 2026, that its shareholders have approved a variation in the objects of its Initial Public Offer (IPO). The approval was granted at an Extraordinary General Meeting held on the same date, enabling the company to revise the utilization of unutilized IPO proceeds.The company’s Board of Directors had previously approved the proposal for the variation, alongside the acquisition of equity shares in M/s. Damaira Pharmaceuticals Private Limited, at a meeting held on February 27, 2026. Shareholders had also previously approved the acquisition of up to 33.33% equity stake in Damaira Pharmaceuticals Private Limited at the Annual...